Lincoln Pharmaceuticals plans to launch Cephalosporin products, acquires plant in Mehsana

Lincoln Pharmaceuticals is planning to launch Cephalosporin products soon. The company has acquired a facility in Mehsana, Gujarat, in this regard. It intends to invest Rs 30 crores in Cephalosporin plant, including capacity expansion and modernisation of the facility. The company will fund the acquisition and capex from internal accruals. The company expects commercial operations from March 2022. The plant is expected to contribute sales of around Rs 150 crores in the next three years. It will cater to all the Cephalosporin products i.e. tablets, capsules, dry syrups and injectables, the company said in a statement.

The acquired facility in Mehsana, Gujarat has been designed as per the PIC’s and European Region. The company is in the process of applying for WHO GMP certifications for the facility and expects to receive the same by December 2021. The company is planning to manufacture 20 plus Cephalosporin products and is planning to start product registration soon for the domestic and exports market, it added.

The statement informed that Cephalosporin is a bactericidal, broad-spectrum, and β-lactam antibiotic originally derived from fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis and others.

Commenting on the development, Mahendra Patel, Managing Director, Lincoln Pharmaceuticals, said, “The entire expansion for Cephalosporin products will be funded from internal accruals. The company has earmarked a total investment of around Rs 30 crores for this expansion. The company expects commercial production of the Cephalosporin products by March 2022. In the next three years, the facility is expected to contribute sales of around Rs 150 crores from domestic markets as well as exports.”

The company plans to manufacture over 20 Cephalosporin products including Cefalexin Oral Suspension BP, Clavulanate tablets, Cefixime capsules and Cefuroxime Axetil tablets, among others. The company also looks to export in African, Latin America and Southeast Asia markets and expand to other markets after necessary approvals, the statement added.